NOX1 and hypertensive disorder: Thus, therapeutic interventions that reduce NOXA1/NOX1 activation and ROS generation in renal epithelial cells and thereby inhibit ENaC hyperactivity may be advantageous in the treatment of chronic kidney disease, diabetes, and therapy resistant HTN.